Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Colorectal Cancer

Gastric Cancers

Liver Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancer

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Graft-Vs-Host Disease

Leukemia

Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematology

Lung Cancer

Pediatric Cancer

Sarcomas

Melanoma

Skin Cancer

CRS is a common but manageable toxicity of CAR T-cell therapy and bispecific antibodies. Learn strategies to identify and manage this adverse effect.

Managing CRS in Hematologic Cancers: A Nursing Perspective

Paolo Tarantino, MD, PhD, discusses ADC structure, toxicity, and nursing consideration for the treatment of patients with breast cancer.

Safer Care in Breast Cancer: Expert Advice for Managing ADC Toxicities

Nurse practitioner Beth Faiman outlines nursing strategies to monitor, assess, and manage toxicities associated with talquetamab in multiple myeloma.

How Nurses Can Assess and Manage Talquetamab Toxicities

Beyond administering CAR T-cell therapy and bispecifics, oncology nurses must apply proactive, supportive care and an understanding of complex treatments.

Transformative Care: A Nurse Guide to Novel Therapies in Blood Cancers

News

Latest News

FDA News

Adverse Event Management

Supportive Care

Disparities in Cancer Care

Drug Safety

Radiation Oncology

Survivorship 

Practice Management

Prevention

Contributors

Media

Expert Connections

Morning Rounds

The Vitals

Podcasts

Videos

Between the Lines

From All Angles

Meeting of the Minds

Training Academy

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Continuing Education

Resources

Case-Based Digest 

Rx Road Map

Webinars

Cancer Summary Slides

MPN Symptom Management

Events

Subscribe

Partners

Michelle Kirschner, RN, MSN, ACNP, APRN-BC, is a nurse practitioner and director of program development at the Cancer Survivorship and Supportive Care Professionals Network.

Bridget Hoyt is the assistant editor for Oncology Nursing News. She earned her BA in communication studies at Rider University with a minor in public relations. She can be reached at 

Catering supportive care to the individual being treated helps better meet the needs of each patient, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

Precision Supportive Care Individualizes Patient Experience

Articles

Gina Mauro currently serves as Vice President of Content at MJH Life Sciences, overseeing 

®. Gina joined the company in 2015 and has held various positions on 

Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com

Experts share advice on tailoring frontline treatment and managing toxicities for individuals with hormone receptor–positive metastatic breast cancer.

A Nurse’s Overview of First-Line Treatment for HR+ Metastatic Breast Cancer

Kelsey Martin, APRN, AG-ACNP-BC, AOCNP, a nurse practitioner at Sarah Cannon Research Institute in Nashville, Tennessee.

Kelsey Martin, APRN, AG-ACNP-BC, AOCNP, discusses current ADCs in breast, bladder, and lung cancer and highlights promising agents in development.

Current and Emerging ADCs Transforming Cancer Care

Nurse practitioners give their advice on making treatment choices based on the patient’s medical history and preferences.

CDK4/6 Inhibitors: How to Tailor Treatment Choices by AEs

Oncology Nursing News connects oncology nurses and APPs with updates on therapy advances, side effect management, and patient-centered cancer care.

About Us

Editorial Board

Contact Us

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Advertise

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News – Clinical Insights for Cancer Care Nurses

Facebook

LinkedIn

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Nurse Navigation

Quality Improvement

1rem

, we ring in the New Year 2023 by combing through 2022 FDA approvals. Listen as associate editor, Lindsay Fischer, recounts key approvals on a month-by-month basis, with input from some of the investigators from behind the research. To read the full information surrounding the approvals, be sure to check out our news coverage below. Other resources can also be found below.

, and for all the engagement in 2022. We look forward to bringing you more oncology news in 2023.

We want to hear from you! Which drugs approved in 2022 have been practice changing? Have you had any difficulty or success in incorporating these novel agents into clinical use? Any challenges with supporting patients on these regimens? Email 

FDA Approves Tebentafusp to Treat HLA-A*02:01 Positive Uveal Melanoma

Cilta-Cel Snags FDA Approval for Relapsed/Refractory Multiple Myeloma

Neoadjuvant Nivolumab Plus Platinum-Doublet Chemotherapy Is Now Approved for Resectable NSCLC

FDA Greenlights Olaparib for BRCA-Mutated, HER2-Negative Breast Cancer

FDA OKs Relatlimab/Nivolumab for Unresectable or Metastatic Melanoma

FDA Approves Pembrolizumab in MSI H/dMMR Advanced Endometrial Carcinoma

FDA Approves 177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Axi-Cel Snags FDA Approval for Second-Line LBCL

FDA Approves Trastuzumab Deruxtecan for Unresectable or Metastatic HER2+ Breast Cancer

FDA Grants Ivosidenib Plus Azacitidine Approval for Newly Diagnosed AML With IDH1 Mutations

FDA Grants Azacitidine Approval For Pediatric Patients With Myelomonocytic Leukemia

FDA Grants 2 Frontline Nivolumab-Based Regimens Approval for Unresectable Advanced or Metastatic ESCC

Tisagenlecleucel Receives FDA Approval for Relapsed or Refractory Follicular Lymphoma

FDA Grants Accelerated Approval to Dabrafenib Plus Trametinib for BRAF V600E–Mutated Solid Tumors

FDA Approves Liso-Cel for Second-Line Large B-Cell Lymphoma

Crizotinib Approved For ALK+ Inflammatory Myofibroblastic Tumors

HER2-Directed Therapy, Trastuzumab Deruxtecan, Approved for Metastatic NSCLC

Trastuzumab Deruxtecan Is Approved for Patients With Metastatic HER2-Low Breast Cancer

FDA Approves Darolutamide Tablets for Select Patients With Prostate Cancer

Capmatinib Snags Full FDA Approval for MET Exon 14 Skipping NSCLC

FDA Grants Ibrutinib Approval for Pediatric Graft-Versus-Host-Disease

FDA Gives Pemigatinib Greenlight for FGFR1 Rearranged Myeloid/Lymphoid Neoplasms

Durvalumab Plus Gemcitabine/Cisplatin Approved by the FDA for Advanced or Metastatic Biliary Tract Cancers

Sodium Thiosulfate Gets Green Light for Chemotherapy-Induced Hearing Loss in Pediatric Patients

Selpercatinib Is Approved for 2 RET Fusion–Positive Solid Tumors, Non–Small Cell Lung Cancer

FDA Approves Futibatinib for Pretreated, Advanced or Metastatic Intrahepatic Cholangiocarcinoma with FGFR2 Rearrangements

FDA Approves Durvalumab in Combination with Tremelimumab for Unresectable HCC

Teclistamab-cqyv Snags Accelerated Approval for Relapsed or Refractory Multiple Myeloma

Cemiplimab Gets Go Ahead In Combination With Chemotherapy For Advanced NSCLC

Brentuximab Vedotin Gets Green Light for High-Risk Hodgkin Lymphoma in Pediatric Patients

Durvalumab/Tremelimumab/Chemotherapy Combination Approved for NSCLC Indication

Mirvetuximab Soravtansine-gynx Gets Go Ahead in Platinum-Resistant Ovarian Cancer

Olutasidenib Approved for IDH1-Mutated Acute Myeloid Leukemia

Adagrasib Receives Accelerated Approval for KRAS G12C Mutated NSCLC

Watch: Newly Approved Tebentafusp Requires Up-Front Active Toxicity Management in Melanoma

Dr. Geyer Highlights Optimal Dosing Strategies for New Olaparib Indication in Breast Cancer

Nurse Takeaways: Latest Pembrolizumab Indication in Endometrial Cancer

Podsada Discusses Biomarker Testing and ADC Therapies in Breast Cancer

Goodwin Provides Nursing Perspective on Recent FDA Approvals in NSCLC

Futibatinib Approval Ushers in Targeted Therapy Option for Patients With Unresectable, Intrahepatic FGFR2-Positive Cholangiocarcinoma

Barber Discusses the Integration of Durvalumab/Chemotherapy Combination as New Standard of Care in Biliary Tract Cancers

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.  

A Look Back at 2022 FDA Approvals in Oncology

, Ellen Miller, MSN, FNP-BC, a nurse practitioner with Vanderbilt University’s Radiation Oncology Survivorship Clinic, shares her experience with a 26-year-old woman who wanted to get pregnant after undergoing chemoradiation for stage II extranodal natural killer T-cell lymphoma of the nasal cavity as a teenager. Miller underscores why some patients may not choose or be able to pursue fertility preservation when they receive a cancer diagnosis, and what follow-up conversations might be necessary for survivors who have family building goals following cancer treatment. 

References and resources are provided below. 

“When I talked with her, I asked her, specifically, ‘Were you offered fertility preservation?’ And she said, ‘Absolutely.’ [But] she declined, she said, ‘I was 19, I didn’t think I wanted kids.’ But she had [since] met her husband, a wonderful man, and decided that she wanted to have kids.” 

“The out-of-pocket [cost] for fertility preservation is $10,000 to $15,000, on average. That’s hard for [anyone], not to mention a young [woman].” 

“Not only can chemotherapy damage existing eggs, but it can also lead patients to have early or premature menopause.” 

“If patients were to have left-sided chest radiation, [for] a lymphoma or maybe even a breast cancer, we would do some cardiac monitoring, since both the chemotherapy and the radiation can be damaging to the heart, and pregnancy can cause the heart to work harder.” 

“[The] trajectory for her experience was pretty standard, and we were thankful for that. But there are some reasons why some women would need further monitoring.” 

Improving Onco-Fertility Conversations With Adolescents and Young Adult Patients With Cancer

Fertility and Family Planning: Supportive Patient Conversations

Quality Oncology Care: Discussing Fertility Preservation for Patients With Breast Cancer

Fertility Preservation Guidelines Urge for Early Discussions With Young Patients with Cancer

Jennifer Levine on Fertility Challenges in Survivors of Childhood Cancer

Gwendolyn Quinn Discusses Fertility Concerns in Childhood Cancer Survivors

Let's Talk About Sex, Fertility, and Intimacy After Cancer

Adolescent and Young Adult Patients Face Unique Needs, Challenges

Is Chemotherapy an Emergency When Fertility Is at Risk?

Female reproductive health. CureSearch for Children’s Cancer. Accessed November 15, 2022. 

Having a baby after cancer: pregnancy. American Cancer Society. March 2019. Accessed November 15, 2022. 

Fertility facts. Leukemia & Lymphoma Society. November 2014. Accessed November 15, 2022. 

Quick guide to fertility preservation. July 2022. Accessed November 15, 2022. 

Cardonick EH. Overview of infertility and pregnancy outcome in cancer survivors. UpToDate. July 24, 2019. Accessed November 15, 2022. 

In this episode of "The Vitals," Ellen Miller, MSN, FNP-BC, talks about meeting a patient who realized she wanted to get pregnant after undergoing chemoradiation as a teenager.

Oncology Nursing Stories: Pregnancy After Lymphoma Chemoradiation 

, we spoke with Donna Herrera Bell, MSN, APRN, FNP-C, an oncology nurse practitioner with The University of Texas MD Anderson Cancer Center (MD Anderson) who spent 14 years working with children and adolescents with leukemia and lymphoma as well as helped develop a Pediatric Onco-Fertility consult service with MD Anderson.

Bell recently presented at the 47th Annual Oncology Nursing Society Congress about eliminating barriers to conversations around fertility preservation for adolescent or young adult patients with cancer. In our discussion, Bell highlights common barriers that young men and women face, reasons why oncology nurses may not always feel comfortable addressing the topic of fertility, and why initiating the conversation and raising fertility risk awareness is crucial following a cancer diagnosis.

“Fertility preservation is not something that everyone can do. But it is something that every [patient should] discuss, and feel empowered about,” Bell says.

, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms, to get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

In this episode of The Vitals, Donna Herrera Bell, MSN, APRN, FNP-C, highlights how nurses can eliminate barriers to fertility discussions among adolescent and young adult patients with cancer.

In this special episode of “The Vitals,” 

® Magazine met with Janice Post-White, PhD, RN, FAAN, to discuss her recently published book, “Standing at Water’s Edge.”

Post-White was an oncology nurse when her 4-year-old son, Brennan, was diagnosed with B-cell acute lymphoblastic leukemia. Throughout our discussion, she reflects on the intersections of her professional and personal life, the lessons she learned, and offers advice for those processing their own grief in the wake of cancer.

“I remember saying to one student, ‘You know, I really need to know more about pediatric oncology.’ And, that year, my son was diagnosed... I guess you have to be careful what you wish for. But what I also learned is that [although] I had a PhD in nursing, and I had a [cancer] background, with a minor in immunology, pathobiology, I was interested in psycho-neuro-immunology, or how the mind and the body communicate. All of my research focused in that area, but none of what I did prepared me to be a cancer mom.”

“I did immune assays in the lab and I studied imagery and massage and mindfulness meditation, healing touch therapies, and everything I [thought] I knew about cancer. I thought I knew what it was. But it was when my son was diagnosed that I learned, I really don't know how to be a [caregiver]. There's a lot more than just knowing and the knowledge; it's really the emotional realm.”

In this episode of “The Vitals,” Dr. Janice Post-White discusses how she balanced working as an oncology nurse through her child’s cancer diagnosis, and the lessons she learned from the experience. 

When an Oncology Nurse Becomes a Cancer Mom: How One Nurse Navigated Her Child’s Leukemia Diagnosis 

Provider communication is extremely important, especially when dealing with a pediatric cancer diagnosis. In this episode of “The Vitals,” Bryan A. Sisk, MD, MSCI, assistant professor of pediatric hematology and oncology at the Washington University School of Medicine discusses his recent research on communication barriers between healthcare providers and children with cancer and their families.

While some of these issues can be found in the broader cancer space, others – like how much information to give a 6-year-old versus a 16-year-old – align more with the intricacies of pediatrics. Sisk talks about this, and the improvements he hopes to see in this space in years to come.

A Chat on Communication Barriers in Childhood Cancer

A recent study led by Bethany J. Petronio-Coia, PhD, RN, a nurse educator at the Rhode Island College School of Nursing, discovered the characteristics of “approachable” nurses caring for school-aged children who were hospitalized for cancer. From compassionate listening to syringe water fights, they shared some creative ways that nurses have managed to make their care a bit less scary. 

https://www.oncnursingnews.com/web-exclusives/a-smiling-nurse-makes-all-the-difference-in-pediatric-oncology

From compassionate listening to syringe water fights, children shared some creative ways that nurses have managed to make their care a bit less scary. 

Capturing the Voice of the Child in Cancer Care

Maria C. Velez, MD, shared that teamwork between pediatric and adult care teams can make the transition of care smoother for AYA patients.

Pediatric Cancer

Latest News

Latest Conference Coverage